As airports grow more complex, the real innovation lies in making their systems simpler, faster, and easier to act on
Updated
March 24, 2026 5:55 PM
An airplane parked at Josep Tarradellas Barcelona-El Prat Airport. PHOTO: UNSPLASH
Airports are some of the most complex systems in the world. Every day, they manage thousands of flights, passengers, crew schedules, gates and ground operations—all moving at the same time. But much of this still runs on older software that doesn’t connect well, making simple decisions harder than they need to be.
This is the gap companies like AirportLabs are trying to address. Instead of relying on multiple disconnected systems, their approach brings airport operations into one cloud-based platform. The goal is straightforward: take scattered data and turn it into something teams can actually use in real time.
In practice, this means combining core systems like flight databases, resource management and display systems into a single interface. When everything is connected, airport staff can respond faster—whether it’s adjusting gate assignments, managing delays, or coordinating ground crews. Rather than reacting late, decisions can be made as situations unfold.
Another shift is how this technology is built. Traditional airport systems often require heavy on-site infrastructure and long deployment timelines. In contrast, cloud-based platforms remove much of that complexity. Updates are faster, systems are easier to scale and teams spend less time maintaining servers and more time improving operations.
What stands out is the speed of adoption. Instead of multi-year rollouts, newer systems can be implemented in weeks, allowing airports to see improvements much sooner.
At a broader level, this reflects a familiar pattern seen across industries. As operations become more data-heavy, the advantage shifts to those who can simplify complexity. In aviation, that doesn’t just mean better technology—it means making the entire system easier to run.
Keep Reading
A new bet on early heart failure detection and why women’s health is at the center.
Updated
January 8, 2026 6:28 PM
A doctor holding an artificial heart model. PHOTO: ADOBE STOCK
Heart disease does not always announce itself clearly, especially in women. Many of the symptoms are ordinary, including fatigue, shortness of breath and swelling. These signs are frequently dismissed or explained away. As a result, many women are diagnosed late, when treatment options are narrower and outcomes are worse. That diagnostic gap is the context behind a recent investment involving Ultromics and the American Heart Association’s Go Red for Women Venture Fund.
Ultromics is a health technology company that uses artificial intelligence to help doctors spot early signs of heart failure from routine heart scans. It has received a strategic investment from the American Heart Association’s Go Red for Women Venture Fund.
The focus of the investment is a long-standing blind spot in cardiac care. Heart failure with preserved ejection fraction, or HFpEF, affects millions of people worldwide, with women disproportionately impacted. It is one of the most common forms of heart failure, yet also one of the hardest to diagnose. Studies even show women are twice as likely as men to develop the condition and around 64% of cases go undiagnosed in routine clinical practice.
Ultromics works with a tool most patients already experience during heart care: the echocardiogram. There is no new scan and no added burden for patients. Its software analyzes standard heart ultrasound images and looks for subtle patterns that point to early heart failure. The goal is clarity. Give clinicians better signals earlier, before the disease advances.
“Heart failure with preserved ejection fraction is one of the most complex and overlooked diseases in cardiology. For too long, clinicians have been expected to diagnose it using tools that weren't built to detect it and as a result, many patients are identified too late,” said Ross Upton, PhD, CEO and Founder of Ultromics. “By augmenting physicians' decision making with EchoGo, we can help them recognize disease at an earlier stage and treat it more effectively.”
The stakes are high. Research suggests women are twice as likely as men to develop the condition and that a majority of cases are missed in routine clinical practice. That delay matters. New therapies can reduce hospitalizations and improve survival, but only if patients are diagnosed in time.
This is why early detection has become a priority for mission-driven investors. “Closing the diagnostic gap by recognizing disease before irreversible damage occurs is critical to improving health for women—and everyone,” said Tracy Warren, Senior Managing Director, Go Red for Women Venture Fund. “We are gratified to see technologies, such as this one, that are accepted by leading institutions as advances in the field of cardiovascular diagnostics. That's the kind of progress our fund was created to accelerate.”
Ultromics’ platform is already cleared by regulators for clinical use and is being deployed in hospitals across the US and UK. The company says its technology has analyzed hundreds of thousands of heart scans, helping clinicians reach clearer conclusions when traditional methods fall short.
Taken together, the investment reflects a broader shift in healthcare. Attention is shifting earlier—toward detection instead of reaction. Toward tools that fit into existing care rather than complicate it. In this case, the funding is not about introducing something new into the system. It is about seeing what has long been missed—and doing so in time.